2 weeks Ago By Defense World Staff
Bank of New York Mellon Corp raised its stake in shares of Contineum Therapeutics, Inc. (NASDAQ:CTNM – Free Report) by 32.3% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission.
The firm owned 18,738 shares of the company’s stock after buying an additional 4,573 shares during the quarter. Bank of New York Mellon Corp owned about 0.07% of Contineum Therapeutics worth $275,000 at the end of the most recent reporting period.
Several other institutional investors also recently modified their holdings of the stock. BNP Paribas Financial Markets boosted its stake in Contineum Therapeutics by 1,248.6% during the 3rd quarter.
BNP Paribas Financial Markets now owns 6,743 shares of the company’s stock worth $129,000 after acquiring an additional 6,243 shares during the last quarter. State Street Corp raised its holdings in Contineum Therapeutics by 23.7% in the third quarter.
State Street Corp now owns 113,566 shares of the company’s stock worth $2,174,000 after purchasing an additional 21,760 shares during the period. Franklin Resources Inc. boosted its position in shares of Contineum Therapeutics by 130.
9% during the third quarter. Franklin Resources Inc. now owns 1,447,550 shares of the company’s stock worth $27,706,000 after purchasing an additional 820,542 shares in the last quarter.
Rhumbline Advisers grew its holdings in shares of Contineum Therapeutics by 36.3% in the 4th quarter. Rhumbline Advisers now owns 8,233 shares of the company’s stock valued at $121,000 after buying an additional 2,191 shares during the period.
Finally, FMR LLC increased its position in shares of Contineum Therapeutics by 115.4% in the 3rd quarter. FMR LLC now owns 696,927 shares of the company’s stock valued at $13,339,000 after buying an additional 373,327 shares in the last quarter.
Contineum Therapeutics Price PerformanceCTNM stock opened at $7.07 on Friday. The stock has a market capitalization of $182.
92 million and a P/E ratio of -1.44. Contineum Therapeutics, Inc.
has a fifty-two week low of $5.92 and a fifty-two week high of $22.00.
The business has a 50-day moving average of $8.23 and a 200-day moving average of $13.24.
Analysts Set New Price TargetsSeveral research firms have weighed in on CTNM. Royal Bank of Canada reiterated an “outperform” rating and set a $31.00 target price on shares of Contineum Therapeutics in a report on Thursday, January 9th.
Jones Trading initiated coverage on Contineum Therapeutics in a report on Thursday, March 13th. They set a “buy” rating and a $23.00 price objective on the stock.
Morgan Stanley reissued an “overweight” rating and set a $25.00 target price on shares of Contineum Therapeutics in a research note on Friday, March 7th. Finally, Robert W.
Baird cut their price target on shares of Contineum Therapeutics from $32.00 to $16.00 and set an “outperform” rating on the stock in a research note on Friday, March 7th.
Five research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat, Contineum Therapeutics currently has an average rating of “Buy” and an average target price of $24.80.
Get Our Latest Report on CTNMAbout Contineum Therapeutics (Free Report)Contineum Therapeutics, Inc, a clinical stage biopharmaceutical company, focuses on discovering and developing novel oral small molecule therapies for neuroscience, inflammation, and immunology indications with high unmet need. Its lead asset is PIPE-791, a novel, brain penetrant, small molecule inhibitor of the lysophosphatidic acid 1 receptor (LPA1R) for the treatment of idiopathic pulmonary fibrosis and progressive multiple sclerosis (MS).Recommended StoriesFive stocks we like better than Contineum TherapeuticsWhen to Sell a Stock for Profit or LossMarketBeat Week in Review – 03/24 – 03/28How to trade penny stocks: A step-by-step guideShould You Buy UPS Stock Now? Deep Dive Into Its 5-Year LowWhat Are the FAANG Stocks and Are They Good Investments?4 Healthcare Stocks With Massive Gains—and More to Come.
